WILMINGTON, Del. — January 14, 2026 — Leads & Copy — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced it has licensed Real World Evidence (RWE) drawn from over 70,000 patients in the United States who were treated with either intravenous ketamine or nasal S-ketamine for depression and suicidal ideation.
The information is being submitted in support of NRx’s application for Accelerated Approval of NRX-100 (preservative-free ketamine) under Fast Track Designation for Treatment of Suicidal Ideation in Depression and Bipolar Depression. Currently, there is no medicine approved to treat suicidal ideation, and the only FDA-approved treatment today is Electroshock Therapy.
The RWE is provided by Osmind, a neuropsychiatry technology and medical records platform used by clinics across the United States. Through this collaboration, Osmind is supplying regulatory-grade real-world evidence (RWE) to the US Food and Drug Administration (FDA) to support NRx’s application for Accelerated Approval of NRX-100 (preservative-free ketamine) as a treatment for suicidal ideation in depression, including bipolar depression.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone).
NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.
Osmind offers an industry-leading real-world dataset on ketamine and esketamine with a large, diverse patient base and a comprehensive set of fit-for-purpose data variables spanning effectiveness and safety with longitudinal capture. This dataset includes nearly one million treatment sessions with ketamine or esketamine, hundreds of millions of datapoints of continuous vitals monitored during treatment, and differentiated data elements such as assessment of bladder symptoms and sedation.
A preliminary analysis of a subset of patients was presented by Osmind at the 2024 meeting of the American Society of Clinical Psychopharmacology. Quantitative comparison to currently-approved products suggested a favorable clinical response. NRx is optimistic that when the full real-world dataset of over 70,000 patients is analyzed, the results will be clinically meaningful. In September 2025, FDA altered its policy to allow the submission of RWE that does not include personally-identifiable patient information, a policy shift that enables the submission of de-identified data from Osmind.
Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals, said the company appreciates Osmind’s partnership in sharing the 70,000 patient Real World dataset in support of NRX-100 approval by the FDA.
According to Javitt, an American commits suicide every 11 minutes and ketamine has become widely used off-label as a drug that has been seen to reduce suicidal ideation in clinical trials. Ketamine has been adopted within the military and veterans communities for this purpose.
Javitt added that only Americans whose care is paid for by the military and the Veterans Administration, along with those who can pay out of pocket, are able to access this potentially valuable medicine. Those who rely on other health insurance are generally not eligible for reimbursement.
NRx is in the process of applying to the FDA for Accelerated Approval of NRX-100 (preservative-free ketamine) to enable broader access of this potentially life-saving medicine under appropriate medical supervision.
Brian Korb, Managing Partner, astr partners, can be reached at (917) 653-5122 or brian.korb@astrpartners.com.
Source: NRx Pharmaceuticals, Inc.
